Take­da suf­fers an­oth­er set­back in its quest to ex­pand myelo­ma drug’s reach — and block­buster po­ten­tial

7 years ago
R&D

Pfiz­er scoops Cal­i­co ex­ec Jeff Set­tle­man to head big on­col­o­gy R&D ops in La Jol­la

7 years ago

For­eign threats to NIH re­search: Sen­ate Fi­nance Com­mit­tee digs in

7 years ago
China

Clock starts tick­ing on Leif Jo­hansson's re­tire­ment from As­traZeneca chair­man role — re­port

7 years ago
People

Deer­field strikes up new deal with Co­lum­bia Uni­ver­si­ty; Ovid CEO Je­re­my Levin joins BIO as new board chair

7 years ago
News Briefing

Ned Sharp­less weighs in on gene ther­a­py pric­ing de­bate, sug­gest­ing 'the mes­sag­ing got lost'

7 years ago
People
Cell/Gene Tx

Mid-stage da­ta on Al­lena's hy­per­ox­aluria drug fu­el op­ti­mism ahead of piv­otal read­out

7 years ago
R&D

In­flaRx shares shat­tered as lead drug flops bad­ly in a PhI­Ib tri­al while Chemo­Cen­tryx is caught in the smash up

7 years ago
R&D
Pharma

Bris­tol-My­ers bumps off chief sci­en­tist in an­oth­er big shake­up, bring­ing in Cel­gene and No­var­tis ex­ecs

7 years ago
People
Pharma

Texas biotech Lung Ther­a­peu­tics clos­es $36M Se­ries C to ad­vance clin­i­cal work for or­phan drugs

7 years ago
R&D

Where Te­va failed, Eli Lil­ly gained — mi­graine drug Em­gal­i­ty wins US ap­proval for episod­ic clus­ter headaches

7 years ago
R&D

The Wash­ing­ton Post points the fin­ger at Pfiz­er for stay­ing mum about an Alzheimer’s study. But there’s more to ...

7 years ago
Bioregnum
Pharma

Spread­ing its wings in Chi­na with glob­al am­bi­tion, EpimAb snags $74M Se­ries B for bis­pe­cif­ic work

7 years ago
Financing
China

Cel­gene/Ac­celeron win speedy FDA re­view for lus­pa­ter­cept in be­ta tha­lassemia; Ko­re­an in­vestor out to shake up ...

7 years ago
News Briefing

Neil Wood­ford force­ful­ly stems in­vestor out­flow by sus­pend­ing his be­lea­guered main fund

7 years ago
People
Financing

Bay­er en­lists Arv­inas on two-pronged pro­tein degra­da­tion ef­fort, for­ay­ing in­to agtech

7 years ago

Weeks af­ter rais­ing $40M, Cel­gene-part­nered In­hi­brx lays ground­work for near­ly $75M pub­lic de­but

7 years ago
Financing

Mer­ck tests an­tibi­otics wa­ters again as FDA OKs Zer­bax­a's ex­pand­ed use in pneu­mo­nia

7 years ago
Pharma

#AS­CO19: MET in­hibitors from In­cyte/No­var­tis and Ger­many's Mer­ck face off for rare sub­set of NSCLC pa­tients

7 years ago
R&D

Add one fa­tal flaw to Jiankui He's litany of mis­takes in CRISPR ba­by de­ba­cle

7 years ago
People
Discovery

EU stamps his­toric OK on blue­bird’s gene ther­a­py for β-tha­lassemia — now sit back and wait for the price

7 years ago
R&D
Cell/Gene Tx

Eye­Gate surges on FDA nod to start piv­otal study; Alde­vron to build gene ther­a­py man­u­fac­tur­ing cam­pus in Far­go, N.D.

7 years ago
News Briefing

J&J, Gen­mab strength­en case for Darza­lex in front­line mul­ti­ple myelo­ma with fresh slate of PhI­II da­ta

7 years ago
R&D

Ma­ligned ex-MiMedx chief Pe­tit wants back on the board — wound care com­pa­ny tells share­hold­ers to say no way

7 years ago
People
First page Previous page 943944945946947948949 Next page Last page
A service from the Financial Times